Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Beijing Konruns Pharmaceutical Co's
Operating Income
for the
three
months ended in Mar. 2026 was ¥61.9 Mil. Beijing Konruns Pharmaceutical Co's Interest Expense for the
three
months ended in Mar. 2026 was ¥-2.2 Mil.
Beijing Konruns Pharmaceutical Co's interest coverage for the quarter that ended in Mar. 2026 was 28.12.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Beijing Konruns Pharmaceutical Co's Interest Coverage or its related term are showing as below:
SHSE:603590'
s Interest Coverage Range Over the Past 10 Years
Min: 20.81 Med: 257.22 Max: 15517.59
Current: 25.68
SHSE:603590's Interest Coverage is ranked worse than 64.63% of 376
companies
in the Biotechnology industry
Industry Median: 106.135
vs SHSE:603590: 25.68
Beijing Konruns Pharmaceutical Co (SHSE:603590) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Beijing Konruns Pharmaceutical Co Interest Coverage Related Terms
Beijing Konruns Pharmaceutical Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Beijing Konruns Pharmaceutical Co Interest Coverage Chart
SHSE:603590 vs VRTX, REGN, RVMD: Interest Coverage Comparison
For the Biotechnology subindustry, Beijing Konruns Pharmaceutical Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Konruns Pharmaceutical Co Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Konruns Pharmaceutical Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Beijing Konruns Pharmaceutical Co's Interest Coverage falls into.
Beijing Konruns Pharmaceutical Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Konruns Pharmaceutical Co (SHSE:603590) has a Interest Coverage of 28.12 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Beijing Konruns Pharmaceutical Co and its competitors. This is 89% below median its historical median of 257.22. Over the past decade, Beijing Konruns Pharmaceutical Co's Interest Coverage has ranged from 20.81 to 15,517.59. According to the industry distribution chart, Beijing Konruns Pharmaceutical Co ranks #243 out of 376 companies in the Biotechnology industry, placing it in the top 64.6%.
Is Beijing Konruns Pharmaceutical Co's Interest Coverage too high?
Beijing Konruns Pharmaceutical Co's current Interest Coverage of 28.12 is 89% below median its 10-year median of 257.22. Over the past 10 years, this metric has ranged from a low of 20.81 to a high of 15,517.59. The Biotechnology industry median Interest Coverage is 106.14. Beijing Konruns Pharmaceutical Co's value of 28.12 is 73.5% below this industry median. Based on the distribution chart, Beijing Konruns Pharmaceutical Co ranks #243 out of 376 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Beijing Konruns Pharmaceutical Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Konruns Pharmaceutical Co's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Konruns Pharmaceutical Co ranks #243 out of 376 companies for Interest Coverage. This places Beijing Konruns Pharmaceutical Co in the lower half of its industry. The industry median Interest Coverage is 106.14. Beijing Konruns Pharmaceutical Co's value of 28.12 is 73.5% below this benchmark. Historically, Beijing Konruns Pharmaceutical Co's own Interest Coverage has ranged from 20.81 to 15,517.59 over the past decade. While the company's 10-year median is 257.22 vs. the industry median of 106.14, Beijing Konruns Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.14, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Konruns Pharmaceutical Co's current Interest Coverage of 28.12 is 73.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Beijing Konruns Pharmaceutical Co and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Konruns Pharmaceutical Co's current Interest Coverage is 28.12, which is 89% below median its own 10-year median of 257.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Konruns Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Konruns Pharmaceutical Co (SHSE:603590) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥35.27, compared to a current price of ¥29.50 — trading 16.4% below its estimated fair value. The current Interest Coverage is 28.12, which is 89% below median its 10-year median of 257.22 and 73.5% below the Biotechnology industry median of 106.14. Beijing Konruns Pharmaceutical Co's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Beijing Konruns Pharmaceutical Co (SHSE:603590), the current Interest Coverage is 28.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Konruns Pharmaceutical Co (SHSE:603590) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Konruns Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥29.50 is trading 16.4% below its estimated GF Value™ of ¥35.27.
GuruFocus considers Beijing Konruns Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603590:
Interest Coverage: 28.12 (89% below median its 10-year median of 257.22)
GF Value™: ¥35.27 vs. price of ¥29.50 (16.4% below fair value)
Industry Position: 73.5% below the Biotechnology median (#243 of 376)
No single metric tells the full story. See the SHSE:603590 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Konruns Pharmaceutical Co Business Description
Beijing Konruns Pharmaceutical Co Ltd is a Chinese pharmaceutical company. It is engaged in the research and development of inventive drugs, and is oriented to clinical needs.
78GF Score
Get the complete analysis for SHSE:603590
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603590 has been successfully added to your 
